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With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment
combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models
to select the most promising combination therapies for entering into phase II clinical trials.
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The shifting paradigm of chemotherapy in hormone
refractory prostate cancer
During the past decades the systemic treatment of most solid
cancers has made multiple developmental steps forward. Today, in
most cancers, first, second and even subsequent lines of therapy
are available, which in addition to relieving symptoms and
delaying disease progression may prolong survival by months or
years, even in the setting of overt metastatic disease. Although the
introduction of new therapeutic agents in areas such as breast
cancer, colorectal cancer and lung cancer has been rather
successful in many aspects, the advent of effective chemotherapy
in hormone refractory prostate cancer (HRPC), unfortunately, has
been one of the exceptions. During the 1980s and 1990s, numerous
single agent chemotherapy trials in HRPC consistently showed
poor overall response rates, without any trend towards improve-
ment in survival (Yagoda and Petrylak, 1993). Based on this
apparent lack of activity of chemotherapy in HRPC, and the
common perception that this elderly patient population was, in
general, too fragile to receive such treatment, patients with HRPC
have not been routinely treated with chemotherapy for many years
and few investigators pursued clinical trials in this field. In 2004,
this paradigm shifted considerably following the results of two
independent phase III studies that showed robust survival
improvement as well as improved symptom relief and improved
quality of life, by the use of docetaxel-based chemotherapy as
compared with the standard regimen of mitoxantrone plus low-
dose prednisone (Petrylak et al, 2004; Tannock et al, 2004). Overall
survival (the primary end point) was superior for the docetaxel
groups compared with mitoxantrone-treated patients. In the
TAX327 study comparing docetaxel every 3 weeks, docetaxel
weekly and mitoxantrone every 3 weeks, all arms with low-dose
prednisone, the median duration of survival was 19.3, 17.8 and 16.3
months, respectively (Berthold et al, 2008). Also, significantly
more patients obtained a pain response and improvement of their
quality of life. The SWOG 99-16 study showed a 2-month survival
benefit of the docetaxel plus estramustine arm (17.5 months) as
compared with the standard therapy of mitoxantrone plus
prednisone (15.6 months). The addition of estramustine to
docetaxel, increased gastrointestinal as well as cardiovascular
toxicity. As a result, in 2004 docetaxel every 3 weeks plus
prednisone became the standard treatment recommendation for
patients with HRPC as approved by the American Food an Drug
Administration (FDA) and European Agency for the Evaluation of
Medical Products (EMEA) (De Wit, 2005).
With the establishment of this new standard reference treatment
for HRPC, this opened the clinical investigational programme of
HRPC for a myriad of phase II and phase III trial options. Today,
at least seven large phase III randomised trials are in progress, all
investigating the potential of adding a new agent to docetaxel every
3 weeks plus prednisone; bevacizumab (CALGB), atrasentan
(SWOG), high-dose pulse calcitriol, DN 101 (Novacea), risedronic
acid (Netherlands-Norwegian study), ZD4054 (AstraZeneca),
GVAX (Cel Genesys) and VEGF trap (Sanofi-Aventis). Many more
options have a similar good rationale, but have not passed the
drawing board of the Pharmaceutical Industries, due to the current
competition and the risk of being faced with a new standard
therapy during trial conduct. As a result, both industries and
investigators hesitate to embark on new large clinical trials at this
point of time.
Surrogate end points in HRPC
A particular additional problem with clinical research in HRPC is
the increasing concern with the usefulness of surrogate end points
(e.g. biomarkers). With the piling number of options for phase III
trials of HRPC, and overall survival being the only accepted end
point, such randomised studies are large and lengthy. The need for
intermediate end points to evaluate treatment effects early in time
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www.bjcancer.comis urgently required. However, alternative end points such as
progression free survival, even if confined to clinical criteria for
progression, has shown to poorly correlate with overall survival
(Di Lorenzo et al, 2007). Serial monitoring of prostate specific
antigen (PSA) is often used as an indicator of treatment response,
but a direct correlation with tumour load and/or outcome has
never been made in the clinical setting (Hadaschik et al, 2007).
Although PSA response may be considered a modest surrogate
measure for survival, this has hardly been tested in the setting of
molecular-targeted agents. Several other (serum) markers have
been proposed as additional or alternative biomarkers or surrogate
end points, but so far these markers are in experimental phase and
lack clinical validation.
Human xenografts for fast-track testing of new therapies
for HRPC
To increase the speed of selection of the large amount of new
options for HRPC, an alternative strategy is proposed that makes
use of human xenograft models of PC as a pre-screening system
(Schro ¨der et al, 2000). Such a xenograft-based pre-screen would
enable a relatively fast selection of the best performing compound,
of new combinations and their optimal sequence, as well as their
potential superiority towards docetaxel treatment. Also, such
preclinical studies would allow for validation of biomarkers, such
as PSA, for their use in subsequent phase II clinical studies. In
xenograft models, circulating levels of PSA can be directly
correlated to tumour burden, allowing validation of the relation-
ship between PSA and tumour response under therapy (Limpens
et al, 2006). This is essential as compounds may interfere with the
regulation of PSA production and/or secretion without affecting
tumour growth, consequently resulting in PSA responses that do
not reflect tumour responses.
PRECLINICAL MODELS OF HUMAN PC
The establishment of PC xenografts and cell lines
The PC research field has long been hampered by the limited
availability of representative model systems. The ‘classical’ models
are the androgen-independent PC3 and DU145 cell lines and the
androgen-responsive LNCaP cell line (Van Bokhoven et al, 2003).
PC3 and DU145 lack expression of androgen receptor and PSA,
characteristics known to be present in HRPC (Ruizeveld de Winter
et al, 1994), and therefore poorly reflect HRPC. Although more
clinically relevant, the androgen responsive, PSA-secreting
LNCaP cell line has its limitation in its poor in vivo tumorigenicity
and in an aberrant response to antiandrogens due to a point
mutation in the ligand binding domain of the androgen receptor
that renders the cells sensitive to not only androgens, but also
to other hormones such as progesterone and oestrogen, as well as
to antiandrogens such as hydroxyflutamide (Veldscholte et al,
1992).
The number of human-derived xenografts have been very few
and only in the early 1990s were we able to establish significant
number of human PC xenograft models (Van Weerden et al, 1996).
This success has triggered other groups, primarily in the United
States, to intensify their efforts resulting in a further extension of
human-derived PC xenografts such as the CWR, MDA Pca, LuCaP
and LAPC series of xenografts established by different groups in
the United States (Table 1). All these xenograft models are made
available to other researchers (Bosland et al, 1996, Navone et al,
1999).The development of permanent cell lines from PC xenografts
has been rather complicated, being successful only for the PC346
xenograft, resulting in the PC346C cell line (Marques et al, 2006).
In recent years, a small number of xenograft-derived cell lines have
been established by other research groups as well. These novel cell
lines PC346C, 22Rv1, CWR-R1, DuCaP, LAPC-4, MDA Pca1, MDA
Pca 2a, MDA Pca 2b and VCaP have all been karyotyped and
compared in an extensive study by van Bokhoven et al (2003).
In Rotterdam, further in vivo and in vitro selection procedures
have resulted in additional PC346 sublines with different
(molecular) characteristics that may be related to the various
stages of PC progression (Marques et al, 2005, 2006). The present
set of xenograft models and cell lines represent the various disease
stages of human PC and strongly add to the options for preclinical
testing.
Xenograft models are very well suited for molecular studies as
they consist of pure human tumour tissue without contamination
of human normal prostate tissue, which is always present in
patient samples. Xenografts have been instrumental to evaluate the
extent of abnormal genetic changes and gene profiles in human PC
by various research groups. Genomic characterisation shows that
specific genomic abnormalities that have been detected in the PC
patient population, such as mutations in the PTEN suppressor
gene and genetic alterations in specific genes are also prevalent in
the xenograft panel (Vlietstra et al, 1998; Maki et al, 2007).
Moreover, xenograft studies revealed TMPRSS2-erg translocations
as well as alternative TMPRSS2-ETV4 translocations that were not
yet detected in men (Hermans et al, 2006, 2008). Knowledge on the
genomic profile of xenografts is crucial also for selecting the most
appropriate preclinical model, especially in the new era of targeted
therapies that require model systems with a specific molecular
expression profile that mimic a specific disease stage or patient
group.
The orthotopic PC xenograft model
The majority of preclinical studies are being performed using
subcutaneous injected tumour cells or xenografts. With the
establishment of several new human PC cell lines from xenografts,
orthotopic injections of PC346C, LAPC4 and LuCaP cell lines into
the mouse prostate have became an attractive alternative for the
traditional subcutaneous xenograft model. This especially holds
true for the evaluation of targeted therapies where expression of
the tissue-specific target is essential and may well be influenced by
the implantation environment.
A drawback of orthotopic transplantation in the mouse prostate
is the difficulty of monitoring tumour growth in time. In the case
of PSA-producing cells, plasma PSA may be used as an indicator of
tumour burden, although this approach would lack validation of
circulating PSA levels to actual tumour load (Thalmann et al,
1996). To allow longitudinal studies in individual mice to evaluate
treatment efficacy, a three-dimensional ultrasound micro-imaging
technique was developed that allows us to frequently monitor
prostate (tumour) volume (Kraaij et al, 2002). For many years, this
micro-imaging technique using transrectal ultrasonography is a
validated and routine procedure to monitor prostate volume in all
our orthotopic studies (Figure 1).
Tumour characteristics of PC xenografts
There is a general feeling that xenograft data have a poor
prediction for human responses in clinical trials. As the three
‘classical’ cell line models, PC3, DU145 and LNCaP, are strongly
overrepresented in these types of studies, this feeling may well
relate to the inappropriate choice of the model system. With the
present generation of xenograft models and the detailed knowledge
of their genomic profiling, it is believed that human xenografts are
very powerful tools to investigate compound efficacy, and to define
compound specificity (in case of a target-specific agent) or identify
(in case no target is known) the mechanism of action. Moreover,
evaluation of combination therapies and their most optimal
sequence of administration are important issues and xenograft
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clinical efficacy.
To perform relevant preclinical studies, the choice of the most
appropriate test model is essential and depends largely on the
patient group for which the treatment is defined and, in relation to
that, the expression of the target of interest. Along with extensive
knowledge of the gene and/or protein expression profiles,
xenograft responses to first-line treatment for PC, hormonal
ablation therapy, and to the second-line treatment, docetaxel, are
additional selection criteria.
Table 1 Human prostate cancer xenograft panel
Name Derived from Androgen responsive PSA AR Year Derived
PC-82 Prostate Yes Yes Yes 1977
PC-133 Bone No No No 1981
PC-135 Prostate No No No 1982
PC-EW Prostate Yes Yes Yes 1981
PC-295 LN Yes Yes Yes 1991
PC-310 Prostate Yes Yes Yes 1991
PC-324 TURP No No No 1991
PC-329 Prostate Yes Yes Yes 1991
PC-339 TURP No No No 1991
PC-346 TURP Yes Yes Yes 1991
PC-346I PC-346 No Yes Mutant 1992
PC-346B TURP Yes Yes Yes 1991
PC-346BI PC-346B No Yes Yes 1992
PC-374 Skin Yes Yes Yes 1992
TEN/12 Prostate Yes Yes Yes 1985
LuCaP 23.1 Lymph node Yes Yes 1996
LuCaP 23.8 Lymph node Yes Yes 1996
LuCaP 23.12 Liver Yes Yes 1996
LuCaP 35 Lymph node Yes Yes Yes 2003
LuCaP 35V LuCaP 35 No 2003
LuCaP 49 Metastasis? No No No 2002
LAPC-3 AI TURP No Yes/no Yes 1999
LAPC-4 AI LN Yes Yes Yes 1997
LAPC-9 AI Bone Met Yes Yes Yes 2001
CWR22 AD Met Yes Yes Mutant 1993
CWR21 AD Met Yes Yes Yes 1993
CWR31 AD Met Yes Yes Yes 1993
CWR91 AD Met Yes Yes Yes 1993
MDA Pca-31 Liver NA 1998
MDA Pca-40 Liver NA 1998
MDA Pca-43 Adrenal NA 1998
MDA Pca-44 Skin NA 1998
AR¼androgen receptor; LN¼lymph node metastasis; MET¼metastasis; NA¼not applicable; PC¼prostate cancer; PSA¼prostate-specific antigen; TURP¼transurethral
resection of the prostate.
bladder
prostate tumour
dorsolateral
ultrasound
probe
pelvic muscle
Figure 1 Transrectal ultrasonography to monitor orthotopic tumour growth in the mouse prostate. PC346C human prostate cancer cells were injected
into the dorsolateral lobe of the mouse prostate and prostate volume was imaged longitudinally Kraaij et al (2002).
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Hormonal ablation treatment, either by surgery or chemically,
have been the hallmark of treatment for advanced PC since the first
studies of Huggins and Hodges in the early 1940s. Since then,
androgen responsiveness and later androgen receptor character-
istics as well as PSA expression have been the most important
determinants for models of PC (see Table 1). Most tumours from
PC patients that no longer respond to endocrine therapy have
retained a functional androgen receptor with often higher levels
than in primary tumours (Ruizeveld de Winter et al, 1994).
Approximately 30% of recurrent tumours show amplification of
the androgen receptor gene with an estimated 10–30% of
antiandrogen-treated patients having a mutated androgen receptor
(Linja and Visakorpi, 2004). These data strongly suggest that the
androgen receptor is still involved in growth regulation of HRPC
and that the presently available antiandrogens (such as flutamide
and bicalutamide) are not capable of blocking this activity in the
HRPC phase of PC. With the increasing knowledge on androgen
receptor activation mechanisms, novel generation androgen
receptor-targeted molecules are being developed that aim to
overcome this resistance by acting better than or differently from
the currently available, conventional androgen receptor anta-
gonists. Also, new efforts are directed towards specific blocking of
enzymes involved in (intratumoural) steroidogenesis as studies
have indicated that HRPC may have the potential capacity to
produce its own androgens (Montgomery et al, 2008). The PC346
xenograft system (Marques et al, 2006) as well as some of the
CWR22, LuCAP and LAPC xenograft lines show progressive,
androgen-independent growth after androgen ablation of tumour-
bearing mice. These resistant, androgen-independent sublines are
valuable assets to study androgen-resistant molecular pathways
(Hendriksen et al, 2006). We also established a set of antiandrogen
(flutamide) resistant PC346C cell lines that mimic the clinical
situation of HRPC. This unique cell line panel that can also be
grown as xenografts, reflects the various mechanisms of androgen
resistance that are also observed in patients, including mutation,
overexpression and downregulation of the androgen receptor
(Marques et al, 2005). Clearly, such cell lines and xenograft models
are instrumental for in vitro and in vivo testing of novel
antiandrogens.
Response to docetaxel
With the establishment of docetaxel as effective treatment for
HRPC, the need for representative test systems to compare
combination strategies became relevant and information regarding
docetaxel responses of the various cell lines and xenograft models
has become an additional selection parameter. In a series of studies
we tested the sensitivity of our xenograft models to one single
injection of docetaxel (33mgkg
 1, i.p.). Of the seven xenografts
that we have tested so far, all responded with tumour growth
reduction, with none showing initial resistance to docetaxel. The
level of response was variable ranging from 50% volume reduction
in the androgen-dependent PC82 tumours to complete remission
of the androgen-independent PC374 tumours. Duration of
response ranged from 14 to 30 days, with an exception for
PC374 that showed long-term individual responses for up to 100
days (Figure 2). An additional injection of docetaxel showed that
relapsed tumours remained sensitive to docetaxel treatment. Also,
injections with a lower dose of docetaxel (17mgkg
 1, i.p.) resulted
in similar response patterns typical for a particular xenograft
although the effect was less pronounced with regard to tumour
inhibition and duration of response (data not shown). The
variability of response of these xenografts to docetaxel treatment
reflects the response profiles that are also observed in the clinic
(Azim and Mok, 2008). To improve magnitude and duration of
clinical responses to docetaxel treatment, new combination
therapies have been proposed. The present xenograft data is
currently providing a solid basis to test these new combinations for
their efficacy to prolong and sustain the initial docetaxel effect in
HRPC.
PRECLINICAL PSA VALIDATION AND PSA-BASED
PHASE II TRIALS
The number of compounds and combination options to be tested
for HRPC are rapidly increasing and demand a fast-track test
system to improve the entrance of promising compounds into
clinical trials. In Rotterdam, we have evaluated a strategy of
parallel testing of new compounds using preclinical xenograft
studies and experimental, PSA-based, short-term clinical phase II
studies (Kranse et al, 2005; Schroder et al, 2005). The xenograft
studies were used to confirm efficacy of the compound as well as to
validate PSA as a surrogate biomarker for therapy response. For
the PSA-based phase II studies hormone naive patients were
selected who were treated by local therapy (radical prostatectomy
or radiation therapy) and who were confronted with rising PSA of
unknown origin. Patients were randomised into a supplement or
placebo group. The study was double-blind and had a crossover
design with a wash-out period in between both treatment periods.
Changes in PSA kinetics were used as parameters. This set-up
allows for concise and short-term studies with a duration
of less than 6 months without loss of statistical power (Schro ¨der
et al, 2000).
In one of the first studies that used this strategy, the effect
of the selective EGFR tyrosine kinase inhibitor gefitinib
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Figure 2 Response of the human prostate xenografts PC-339 (A) and PC374 (B) to docetaxel treatment. Docetaxel was administered as one bolus
injection i.p. of 33mgkg
 1 to mice on day 0 when tumours reached a size of approximately 500mm
3. Tumour volume was recorded by transrectal
ultrasound (A) and calipers measurements (B). Mean growth curves (mean±s.e.m.) represent data from six animals per group.
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similar studies with the CWR22 xenograft (Sirotnak et al, 2002), we
were unable to show a tumour inhibitory effect of gefitinib (daily
oral doses of 50, 100 and 200mgkg
 1) on orthotopic tumour
growth or PSA release of PC346C, whether given to established
tumours (4200mm
3) or directly after tumour inoculation
(Limpens et al, 2005). However, although not effective, Iressa did
not preferentially interfere with PSA release and, thus, could be
considered as a surrogate biomarker for tumour response under
Iressa therapy in the clinical setting. Indeed, additional clinical
studies confirmed the limited activity of gefitinib as monotherapy
in PC (Schro ¨der, 2003). Further molecular studies in our PC346
cell line model revealed that, although gefitinib effectively blocked
EGFR phosphorylation in PC cell lines, it failed to decrease the
constitutively high Akt activity that is present in those PC lines
that have a non-functional Pten (PC3, LNCaP, PC346C). As Pten
loss is a frequent event in PC, this may well explain the low
sensitivity of PC cells to gefitinib.
A second series of experiments that used this screening strategy
were based on the evaluation of dietary supplements to delay PC
progression. Differences in incidence rates of clinical PC with low
incidence rates in Asian countries and high rates in Europe and the
United States, have since long suggested a role of life style factors
such as diet, in PC progression. Epidemiological data and
intervention studies have further triggered a number of large-
scale prevention and intervention studies. Also, experimental
studies using both human PC cell lines and xenografts have been
performed to elucidate mechanisms of chemopreventive action of
a variety of dietary agents. As the number of supplement
combinations and dosages are nearly infinite, our selection
strategy using both PC xenografts and PSA-based clinical phase
II study was used to identify the most potential combinations. Two
randomised double-blind and placebo-controlled PSA-based phase
II studies have been performed in Rotterdam with two different
oral supplements constituted of several dietary nutrients including
soy isoflavones, lycopene, selenium and antioxidants. Both studies
showed prolongation of PSA doubling time when patients received
the supplement, suggesting reduction in tumour progression
(Kranse et al, 2005; Schroder et al, 2005). In a third preclinical
study, the antitumour effect of two dietary nutrients, synthetic
lycopene and vitamin E, was tested. The experimental study
revealed a significant inhibition of orthotopic PC346C tumour
growth in those animals that had received low-dose lycopene plus
low-dose vitamin E as compared with control animals Limpens
et al, 2005). These tumour responses could be reproduced when
using PSA as parameter, indicating no preferential effect of the
supplement on PSA release. Based on this outcome, a PSA-based
clinical phase II study is currently in progress in Germany.
CONCLUSION
The introduction of docetaxel as effective treatment for HRPC
has generated the need for fast-track screening to select new
therapeutic agents and potential treatment combinations, thereby
facilitating the proper design of phase II and phase III clinical
trials. The generation of a substantial number of relevant PC
xenografts and cell lines with stage-specific characteristics
has significantly improved the potential application of preclinical
models for testing of therapy efficacy. Docetaxel treatment of PC
xenograft-bearing mice have shown that these xenograft responses
mimic the clinical situation of HRPC and new combination
therapies with docetaxel can now be evaluated in these xenografts.
Such preclinical studies will also provide essential data on the
relation between tumour volume and PSA responses allowing
for the validation of PSA as potential surrogate marker in
consecutive clinical studies. The concept of combining preclinical
xenograft studies to PSA-based early phase II clinical trials allows
for concise and relatively high-throughput selection system. Such a
set-up has shown its value for the treatment of hormone naive
patients and may also be applicable to improve the management
of HRPC.
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